
Complete Regression of Hepatoblastoma after Interleukin-15– and Interleukin-21–Coexpressing CAR T-Cell Therapy | New England Journal of Medicine nejm.org/doi/full/10.1056/NE… @seattlechildren @TexasChildrens @NIH

Please, find us on Bluesky. I will not support a platform whose owner, an unelected official, is actively damaging the US government including the NIH.

Complete Regression of Hepatoblastoma after Interleukin-15– and Interleukin-21–Coexpressing CAR T-Cell Therapy | New England Journal of Medicine nejm.org/doi/full/10.1056/NE… @seattlechildren @TexasChildrens @NIH

RSV vaccines slash infections: data show jabs’ staggering success against dangerous virus nature.com/articles/d41586-0…

Rewriting the script for solid tumour therapies nature.com/articles/d42473-0…


Excited to share our work in @NEJM! A child with refractory hepatoblastoma achieved a durable complete response after IL-15/IL-21 GPC3 CAR T cells. Grateful to the patient & family and @AndrasHeczey, @CAGT, @BCM, @TexasChildrens, @SeattleChildrens & @NIH! nejm.org/doi/10.1056/NEJMc26…

Please, find us on @bluesky . I will not support a platform whose owner, an unelected official, is actively and ruthlessly damaging the US government including the NIH.

How #scientists make #breakthroughs: a journey to finding a promising method to address #CARTcell challenges in treating #solidTumors. @HeczeyAndras ZP Sumazin, C Rooney, M Brenner @davidsteffin @bcmhouston @TexasChildrens @CAGTHouston @Nature blogs.bcm.edu/2025/01/28/fro…


Eight years of legal fighting came down to this one moment nature.com/articles/d41586-0…


Collectively, these results demonstrate that IL-15 increases the expansion, intratumoural survival and antitumour activity of GPC3 CAR T cells in patients. @NIH @BCMCancerCenter @TexasChildrens @Nature @CPRITTexas

Compared with non-responders, tumour-infiltrating 15.CAR T cells from responders showed repression of SWI/SNF epigenetic regulators and upregulation of FOS and JUN family members, as well as of genes related to type I interferon signalling.

Infusion of 15.CAR T cells was associated with increased incidence of cytokine release syndrome, which was controlled with IL-1/IL-6 blockade or rapidly ameliorated by activation of the inducible caspase 9 safety switch.

Cohort 2 patients (NCT05103631 and NCT04377932) received GPC3 CAR T cells that co-expressed IL-15 (15.CAR), which mediated significantly increased cell expansion and induced a disease control rate of 66% and antitumour response rate of 33%.

Cohort 1 patients (NCT02905188 and NCT02932956) received GPC3 CAR T cells, which were safe but produced no objective antitumour responses and reached peak expansion at 2 weeks.

Glypican-3 (GPC3) is expressed in a group of solid cancers, and here we report the evaluation in humans of the effects of IL-15 co-expression on GPC3-expressing CAR T cells (hereafter GPC3 CAR T cells).